Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 1, 2016

View Archived Issues

European orphan drug designation for fimaporfin to treat cholangiocarcinoma

Good Doctor Pharmaceutical Group reports new PDE inhibitors

Oncocure Biotechnology patents CRM1 inhibitors

Glenmark Pharmaceuticals discloses ADH5 inhibitors

Constellation Pharmaceuticals describes EZH2 inhibitors

PsychoGenics and Sunovion Pharmaceuticals develop antidepressants

Daewoong Pharmaceutical announces Nav1.7 sodium channel blockers

Latanoprost-eluting contact lenses demonstrate IOP-lowering effects in vivo

Betagenon and Baltic Bio start phase IIa trial of O-304

Kleo licenses IP rights from Yale, completes Series A funding

Scientists identify novel disease-causing mutations in DSP gene

European Commission approves Pfizer's crizotinib for ROS-1 positive NSCLC

Novartis presents new tetrahydroisoquinoline with good oral bioavailability in vivo

Mallinckrodt completes Stratatech acquisition

Forma Therapeutics meets development milestone in collaboration with Celgene

Aptahem reports on anticoagulant effect of APTA-1 in animal studies

Facio establishes tool to aid in FSHD drug discovery

AbbVie reports development of selective BET family bromodomain inhibitors

Neurocrine submits NDA for valbenazine in the treatment of tardive dyskinesia

SK Chemicals launches SKYCellflu Quadrivalent influenza vaccine in South Korea

MK-8449: a second generation SYK/ZAP70 inhibitor from Merck

FDA awards Santhera USD 246,000 for the development of omigapil

Intramyocardial AdVEGF-DdNdC gene therapy shows potential in patients with refractory angina

Santen and Kerui establish ophthalmic joint venture in China

NIAID grant supports Sedia's development of HIV test for recent infections

Expected efficacy not observed in Japanese phase II/III study of HP-3150 for cancer pain

FDA grants orphan drug designation to nivolumab for the treatment of esophageal cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.